Garuda Therapeutics’ Post

BlueRock Therapeutics and Bayer’s update about the first stem cell human trial for #Parkinson’s disease IS the highlight of 2024! I have mentioned the study previously in my episode about stem cell therapy. But with the latest news, it deserves a dedicated video! Watch my latest episode 👇 to learn about the study and what’s next! #parkinsonsdiseaseresearch #stemcelltherapy

We don’t put enough merit into this. Once upon a time, I was asked to perform karyotyping on our iPS cell lines. It’s expensive so not all labs routinely do it, but it should be done every 10 passages. iPSCs are very sensitive and their chromosomes can change in an instant. One of my cell lines were showing beautifully round colonies with distinct edges. Compared to another cell line that was barely attaching, it’s attachment efficiency and fold expansion were great. I thought they’ll be karyotypically fine 😀 Boy was I wrong! All 20 of the cells were mutated! It was actually the poorly growing ones that showed less karyotypic abnormalities. 🤮😑 Arguably, that they grew well is like they had cancer cell like properties 🤔 A few points: - Don’t be fooled by your eyes with your day to day cell culture. Always do the actual tests. - Treat iPSCs with the utmost care. Whilst I said the poorly growing ones had less abnormalities, they had only been in culture for 2 passages and still turned up issues. - Stop assuming that at your early stage of research, that it should be OK. The healthier cells were clearly performing very differently to the unhealthy ones. If they don’t behave normally in controlled lab conditions, they won’t behave normally in an animal or human trials. - If you do the testing, you can submit the reports to a journal in the initial stages. They will have more confidence in your results moving forward. Thanks to Prof. Laurie A. Boyer for teaching me all the above!

Have you ever wondered which methods are out there to culture haematopoietic stem cells? Here we review progress and challenges facing the field today!

RANGA RAO RANGARAJU Harit Chaturvedi Dr. Sangita Reddy Preetha Reddy Suparno Chakrabarti vinod raina Dr. Suversha Khanna Such excellent work is being done in Bone Marrow Transplantation in Delhi...yet the lack of coordination between programs is leading to non standardization of protocols...internationally the NRM of Haploidentical transplants is around 8- 10%. This brilliant editorial points out the wide variation of NRM in India between 5 to 40%...only non-standardization of protocols and may be antibiotic usage patterns can explain this. Antibiotic resistance has become a scourge in India due to unregulated use. I am very proud of Mehta et al courageously publishing their results showing the real state of affairs. This paper should have been published in Blood Advances. In fact it should be resubmitted to ASH 2024 and Blood with the Solomon et al and Fuchs et al analysis of HLA Class II mismatch rates. Delhi has the potential of becoming what Boston and Houston are to Cancer Research and Treatment.

Innovation of Stem Cell Therapy for Senescence-Related Diseases Thanks to doc Irene Natalia Nesta Sihombing Innovation of Stem Cell Therapy for Senescence-Related Diseases

Our manuscript "A New Tool Supporting the Selection of the Best Hematopoietic Stem Cell Donor by Modelling Local Own Real-World Data" is now available online as a pre-print version: https://lnkd.in/d36K6nkt A tentative of combining patient-donor HLA and non-HLA characteristics for the choice of the best donor #HLA #StemCells #Transplantation #Donors

Exciting updates on MPN and MF research from Alan Skarbnik! Learn about metformin, CHZ868, MPN classification, and early stem cell transplant insights from #ASCO24: https://lnkd.in/dP_zZRXH

In this review, we highlight the recent successes and remaining challenges of the human induced pluripotent stem cell derived smooth muscle cell model https://lnkd.in/gPVv4-As

Highly pure and highly bioactive mouse and human Leukemia Inhibitory Factor (LIF) for stem cell cultures. #GrowthFactors #stemcells #aurorabiolabs https://t.ly/zRzG0

Attention therapy developers! Check out these useful, recently published, open access publications iPSirius has contributed to: Risk Mitigation in Stem Cell Therapies: Discover strategies to address the key challenges in developing pluripotent stem cell therapies, ensuring smoother paths to commercialization. https://lnkd.in/eHXRz7e2 Advancements in iPSCs: Explore the latest in induced pluripotent stem cells and their therapeutic potential in this detailed Cytotherapy article. Check it out https://lnkd.in/eEZkGCpP Navigating the Regulatory Pathway: Learn how iPSirius is navigating the health, economic, and regulatory landscape toward clinical trials. Full case study https://lnkd.in/eYiwQjws #StemCells #iPSCs #CellTherapy #Immunotherapy #iPSirius